Report Detail

Request for Sample of this report

Other Global Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2020-2026

  • RnM3911408
    • |
  • 06 March, 2020
    • |
  • Global
    • |
  • 125 Pages
    • |
  • HJResearch
    • |
  • Other

Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncolytic Virus Cancer Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncolytic Virus Cancer Immunotherapy market in terms of revenue.
Players, stakeholders, and other participants in the global Oncolytic Virus Cancer Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Oncolytic Virus Cancer Immunotherapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Oncolytic Virus Cancer Immunotherapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncolytic Virus Cancer Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncolytic Virus Cancer Immunotherapy market.
The following players are covered in this report:
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Monoclonal Antibodies
      • 1.4.3 Checkpoint Inhibitors
      • 1.4.4 Oncoloytic Viral Therapies and Cancer Vaccines
    • 1.5 Market by Application
      • 1.5.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2020 VS 2026
      • 1.5.2 Lung Cancer
      • 1.5.3 Breast Cancer
      • 1.5.4 Colorectal Cancer
      • 1.5.5 Melanoma
      • 1.5.6 Prostate Cancer
      • 1.5.7 Head and neck Cancer
      • 1.5.8 Ovarian Cancer
      • 1.5.9 Pancreatic Cancer
      • 1.5.10 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Oncolytic Virus Cancer Immunotherapy Market Perspective (2015-2026)
    • 2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Regions
      • 2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Share by Regions (2015-2020)
      • 2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Oncolytic Virus Cancer Immunotherapy Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Oncolytic Virus Cancer Immunotherapy Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Market Size
      • 3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2015-2020)
      • 3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
      • 3.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2019
    • 3.3 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
    • 3.4 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
    • 3.5 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2015-2020)
    • 4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2021-2026)

    5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application (2015-2026)

    • 5.1 Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)
    • 5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 6.2 Oncolytic Virus Cancer Immunotherapy Key Players in North America (2019-2020)
    • 6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 7.2 Oncolytic Virus Cancer Immunotherapy Key Players in Europe (2019-2020)
    • 7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    8 China

    • 8.1 China Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 8.2 Oncolytic Virus Cancer Immunotherapy Key Players in China (2019-2020)
    • 8.3 China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 8.4 China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 9.2 Oncolytic Virus Cancer Immunotherapy Key Players in Japan (2019-2020)
    • 9.3 Japan Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 9.4 Japan Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 10.2 Oncolytic Virus Cancer Immunotherapy Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    11 India

    • 11.1 India Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 11.2 Oncolytic Virus Cancer Immunotherapy Key Players in India (2019-2020)
    • 11.3 India Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 11.4 India Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size (2015-2020)
    • 12.2 Oncolytic Virus Cancer Immunotherapy Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2015-2020)
    • 12.4 Central & South America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2015-2020)

    13Key Players Profiles

    • 13.1 AstraZeneca
      • 13.1.1 AstraZeneca Company Details
      • 13.1.2 AstraZeneca Business Overview and Its Total Revenue
      • 13.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020))
      • 13.1.5 AstraZeneca Recent Development
    • 13.2 Amgen
      • 13.2.1 Amgen Company Details
      • 13.2.2 Amgen Business Overview and Its Total Revenue
      • 13.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.2.5 Amgen Recent Development
    • 13.3 F Hoffman-La Roche
      • 13.3.1 F Hoffman-La Roche Company Details
      • 13.3.2 F Hoffman-La Roche Business Overview and Its Total Revenue
      • 13.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.3.5 F Hoffman-La Roche Recent Development
    • 13.4 Bristol-Myers Squibb
      • 13.4.1 Bristol-Myers Squibb Company Details
      • 13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
      • 13.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.4.5 Bristol-Myers Squibb Recent Development
    • 13.5 Novartis AG
      • 13.5.1 Novartis AG Company Details
      • 13.5.2 Novartis AG Business Overview and Its Total Revenue
      • 13.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.5.5 Novartis AG Recent Development
    • 13.6 Merck & Co., Inc.
      • 13.6.1 Merck & Co., Inc. Company Details
      • 13.6.2 Merck & Co., Inc. Business Overview and Its Total Revenue
      • 13.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.6.5 Merck & Co., Inc. Recent Development
    • 13.7 Pfizer
      • 13.7.1 Pfizer Company Details
      • 13.7.2 Pfizer Business Overview and Its Total Revenue
      • 13.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.7.5 Pfizer Recent Development
    • 13.8 Biovex
      • 13.8.1 Biovex Company Details
      • 13.8.2 Biovex Business Overview and Its Total Revenue
      • 13.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.8.5 Biovex Recent Development
    • 13.9 Cell Genesys
      • 13.9.1 Cell Genesys Company Details
      • 13.9.2 Cell Genesys Business Overview and Its Total Revenue
      • 13.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.9.5 Cell Genesys Recent Development
    • 13.10 Crusade Laboratories
      • 13.10.1 Crusade Laboratories Company Details
      • 13.10.2 Crusade Laboratories Business Overview and Its Total Revenue
      • 13.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
      • 13.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 13.10.5 Crusade Laboratories Recent Development
    • 13.11 Genelux Corporation
      • 10.11.1 Genelux Corporation Company Details
      • 10.11.2 Genelux Corporation Business Overview and Its Total Revenue
      • 10.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
      • 10.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 10.11.5 Genelux Corporation Recent Development
    • 13.12 Lokon Pharma
      • 10.12.1 Lokon Pharma Company Details
      • 10.12.2 Lokon Pharma Business Overview and Its Total Revenue
      • 10.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
      • 10.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 10.12.5 Lokon Pharma Recent Development
    • 13.13 MultiVir
      • 10.13.1 MultiVir Company Details
      • 10.13.2 MultiVir Business Overview and Its Total Revenue
      • 10.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
      • 10.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2015-2020)
      • 10.13.5 MultiVir Recent Development

    14Analyst's Viewpoints/Conclusions

      15Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on Oncolytic Virus Cancer Immunotherapy. Industry analysis & Market Report on Oncolytic Virus Cancer Immunotherapy is a syndicated market report, published as Global Oncolytic Virus Cancer Immunotherapy Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Oncolytic Virus Cancer Immunotherapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$3,500.00
      		$7,000.00
      		2,810.50
      		5,621.00
      		3,283.00
      		6,566.00
      		540,505.00
      		1,081,010.00
      		292,740.00
      		585,480.00
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo